COVID-19 shows symptoms only 11 to 14 days after contamination. Daily screening of antibodies will help to prevent a coronavirus outbreak in your workforce at its early stages. The BioMedomics test is developed to be easily run by a company nurse or any other health personnel you have in your company.
There are four possible results in this test. The Control line ( C ) should be displayed in all of them to signify correct testing with valid results.
The Control line alone ( C ) signifies the negative result, in which there aren’t any antibodies detected in the blood sample. If C is not displayed, the test is incorrect and should be re-run.
If C and M lines are displayed, the test is valid and displays the detection of lgM antibodies. These antibodies appear in the earliest stages of COVID-19 disease.
If the G line appears alongside the quality control line C, the test is valid and positive for lgG antibodies. The lgG antibodies are present in the blood in the later stages of the Coronavirus disease.
If all lines are visible, the test is positive for lgM as well as lgG antibodies. The presence of both antibodies clearly indicates the current stage of the infection.
The BioMedomics IgM-IgG Combined Antibody Rapid Test is one of the first few certified tests for precise screening of the novice coronavirus infection. This accurate test is developed by BioMedomics using the successful mechanisms of the tests used by the Chinese Center for Disease Control and is available for wholesale purchases. The test is providing precise results by testing a finger-prick blood test for the presence of both LGM and lgG antibodies in the sample.
The BioMedomics test for Coronavirus detects antibodies, the first flags of an infection that can be detected way before any visible symptoms. Immunoglobulin, or lgM, is the largest and most common antibody and is the organism’s first reaction to a contagion. The lgM antibody provides a wide first defense against the virus in the first days of the disease. In the next step, lgG antibodies are more precise and constructed inside the organism to fight the virus and build the long term immunity and immune memory for the virus. Testing for both lgM and lgG antibodies provides a certain identification of COVID-19 disease days before any comprehensible or visible symptoms, together with its stage, and helps to prevent further spreading within your colleagues.
Thus, this combined antibody test could also provide information on the stage of infection.Buy wholesale tests
The COVID-19 Coronavirus screening test allows detection of the novelty SARS-nCoV-2 disease days before any outside symptoms.
The BioMedomics finger-prick blood screening test identifies the lgM and lgG antibodies that correspond to different early stages of the COVID-19 disease.
The testing takes 15 minutes for the finger-prick blood sampling to full interpretation of the result.
The BioMedomics Coronavirus test fully conforms with the Essential Requirements Annex I of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The accuracy of lgM detection is 99.2%, and the accuracy of lgG detection is 99.5%.
The test can display three lines. Control line C should be displayed with any successful test, and if it is alone, the test is negative. The M line corresponds to the presence of lgM antibodies, and the G line indicates the lgG antibodies in the given blood sample.
AMBIGUUS LTD collects and processes your personal data through the website, including any data you may provide through the website when you contact us via contact page or live chat [if applicable].
AMBIGUUS LTD is the controller and responsible for your personal data.
The data that AMBIGUUS LTD collects about you:
Personal data, or personal information, means any information about an individual from which that person can be identified. It does not include data where the identity has been removed (anonymous data).
We may collect, use, store and transfer the following different kinds of personal data about you.
Identity Data includes first name, last name, username or similar identifier, title, date of birth, job title & company name.
Contact Data includes home address, email address and telephone number.
Technical Data includes internet protocol (IP) address, browser type and version, time zone setting and location, browser plug-in types and versions, operating system and platform and other technology on the devices you use to access our website.
Usage Data includes information about how you use our website, products and services.
Marketing and Communications Data includes your preferences in receiving marketing from us and our third parties and your communication preferences.
We also collect, use and share Aggregated Data such as statistical or demographic data for any purpose. Aggregated Data may be derived from your personal data but is not considered personal data in law as this data does not directly or indirectly reveal your identity. For example, we may aggregate your Usage Data to calculate the percentage of users accessing a specific website feature. However, if we combine or connect Aggregated Data with your personal data so that it can directly or indirectly identify you, we treat the combined data as personal data which will be used in accordance with this privacy notice.
We use different methods to collect data from and about you including through:
Direct interactions. You may give us your Identity, Contact and by filling in forms or by corresponding with us by post, phone, email or otherwise. This includes personal data you provide when you:
Automated technologies or interactions. As you interact with our website, we may automatically collect Technical Data about your equipment, browsing actions and patterns. We collect this personal data by using cookies and other similar technologies.
Third parties or publicly available sources. We may receive personal data about you from various third parties as set out below:
Technical Data from the following parties:
We may only use your personal data when the law allows us to. Your personal data can be used in the following circumstances:
Where we need to perform the contract, we are about to enter into or have entered into with you.
Where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests.
Where we need to comply with a legal or regulatory obligation.
Note that we may process your personal data for more than one lawful ground depending on the specific purpose for which we are using your data.
We do our best to protect your personal data from being accidentally lost, destroyed, used, accessed in unauthorized way, altered, and disposed. We take appropriate physical, electronic and managerial measures to ensure that the data disclosed to us is kept secure, accurate and up to date, and kept for only as long as is necessary for the purposes for which it is used. For finance reasons some information may be retained for longer.
The term AMBIGUUS LTD, “us”, “we” shall refer to the:
The following organizations may link to our Website without prior written approval:
These organizations may link to our home page, to publications or to other Website information so long as the link: (a) is not in any way deceptive; (b) does not falsely imply sponsorship, endorsement or approval of the linking party and its products and/or services; and (c) fits within the context of the linking party’s site.
We may consider and approve other link requests from the following types of organizations:
We will approve link requests from these organizations if we decide that: (a) the link would not make us look unfavorably to ourselves or to our accredited businesses; (b) the organization does not have any negative records with us; (c) the benefit to us from the visibility of the hyperlink compensates the absence of AMBIGUUS LTD; and (d) the link is in the context of general resource information.
These organizations may link to our home page so long as the link: (a) is not in any way deceptive; (b) does not falsely imply sponsorship, endorsement or approval of the linking party and its products or services; and (c) fits within the context of the linking party’s site.
If you are one of the organizations listed in paragraph 2 above and are interested in linking to our website, you must inform us by sending an e-mail to AMBIGUUS LTD. Please include your name, your organization name, contact information as well as the URL of your site, a list of any URLs from which you intend to link to our Website, and a list of the URLs on our site to which you would like to link. Wait 2-3 weeks for a response.
Approved organizations may hyperlink to our Website as follows:
No use of AMBIGUUS LTD's logo or other artwork will be allowed for linking absent a trademark license agreement.
We reserve the right to request that you remove all links or any particular link to our Website. You approve to immediately remove all links to our Website upon request. We also reserve the right to amen these terms and conditions and it’s linking policy at any time. By continuously linking to our Website, you agree to be bound to and follow these linking terms and conditions.
To the maximum extent permitted by applicable law, we exclude all representations, warranties and conditions relating to our website and the use of this website. Nothing in this disclaimer will:
The limitations and prohibitions of liability set in this Section and elsewhere in this disclaimer: (a) are subject to the preceding paragraph; and (b) govern all liabilities arising under the disclaimer, including liabilities arising in contract, in tort and for breach of statutory duty.
As long as the website and the information and services on the website are provided free of charge, we will not be liable for any loss or damage of any nature.